CD38 and Miyoshi myopathy: Anti-CD38 antibodies mediate anti-myeloma activity through multiple mechanisms of action both in patients with RRMM and with newly diagnosed MM, although immunomodulatory effects may be greater in earlier disease settings in which the immune system has not been affected by prior treatments [85].